CytomX Therapeutics Inc (NAS:CTMX)
$ 1.02 0 (0%) Market Cap: 79.82 Mil Enterprise Value: -27.17 Mil PE Ratio: 6.00 PB Ratio: 0 GF Score: 52/100

CytomX Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 11, 2024 / 01:15AM GMT
Release Date Price: $1.69 (+1.20%)
Anupam Rama JPMorgan Chase;Co.;Analyst

&-

Welcome everyone to the 42nd Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by my squad, [Lorrea Hall], Priyanka Grover, and Malcolm Kuno.

Our next presenting company is CytomX and presenting on behalf of the company, we have CEO, Sean McCarthy. Sean?

Sean McCarthy CytomX Therapeutics
Inc. - CEO and Chairman

Great. Thanks, Anupam. Great to be here. Thanks very much to the JPMorgan team for the invitation to the conference. I will -- in the course of the next 30 minutes or so, I will be making certain forward-looking statements. I refer you to our SEC filings. So today in my presentation, I will review our multi-modality Probody therapeutic pipeline, which is designed to address major unmet needs in oncology. Let me start with a brief company snapshot.

We're a South San Francisco-based clinical-stage oncology-focused company, developing a pipeline centered on our unique and differentiated

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot